05 September, 2024 in Investor Relations Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
29 July, 2024 in Investor Relations, Videos Discover Nexalin’s Neurostimulation Device Targeting Mental Health Disorders
18 July, 2024 in Investor Relations Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
01 July, 2024 in Investor Relations Nexalin Technology Announces Closing of $5.2 Million Public Offering
27 June, 2024 in Investor Relations Nexalin Technology Announces Pricing of $5.2 Million Public Offering
26 June, 2024 in Investor Relations Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
20 June, 2024 in Investor Relations Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
13 June, 2024 in Investor Relations Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
04 June, 2024 in Investor Relations Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
03 June, 2024 in Investor Relations FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
